Panagene teams up with Yuhan to develop companion diagnostic for Leclaza (Korea Biomedical Review)
"Panagene said on Monday it signed a contract with Yuhan Corp. to jointly develop the original companion diagnostic (CDx), called PANAMutyper R EGFR, for Yuhan’s lung cancer drug Leclaza (lazertinib)....A Yuhan official said that pursuing clinical trials and licensing of PANAMutyper R EGFR as the original companion diagnosis of Leclaza together with Panagene, a leader in domestic companion diagnosis, will be a new milestone in the development of CDx in Korea."